Amgen (Longmont)

Aranesp® for the treatment of anemia caused by chronic kidney failure or chemotherapy

Amgen (Longmont)

Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Epogen® has the same biological effects as endogenous erythropoietin.

Amgen (Boulder)

Kineret® for the reduction in signs and symptoms of rheumatoid arthritis in adult patients who have an inadequate response to other disease modifying antirheumatic drugs.

Pharmion (Schering AG)

Refludan® for the treatment of heparin-induced thrombocytopenia type II and thromboembolic disease in adults mandating parenteral antithrombin therapy - an infrequent but potentially life-threatening response to heparin therapy

Roche (Boulder)

Rocaltrol® is for the treatment of bone-reducing osteoporosis.

Roche (Boulder)

Tamiflu® is the #1 doctor prescribed anti-viral for the treatment of influenza (flu).

Roche (Boulder)

Valcyte® an antiviral agent prescribed to slow the spread of and prevent cytomegalovirus infection in immunocompromised individuals, including transplant recipients and people with AIDS.

Roche (Boulder)

Invirase® a protease inhibitor developed for use in combination with other medicines, such as AZT, to fight the onset of AIDS in people who are HIV positive

Roche (Boulder)

Fuzeon® The first in a new class of anti-HIV drug, known as fusion inhibitors, that prevents the HIV virus from infecting healthy T-cells. The active ingredient in Fuzeon™ is a 36 string amino acid peptide that has been considered the most complex drug ever chemically synthesized at such a large scale.

Pharmion (LEO Pharma)

Innohep® For the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with the oral anticoagulant warfarin sodium.

Pharmion (Celgene)

Thalidomide® approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma after the failure of standard therapies and the acute treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum.

Pharmion (Pharmacia / Pfizer)

Vidaza® for the treatment of all five subtypes of Myelodysplastic Syndromes (MDS) these subtypes include: refractory anemia or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

OSI Pharma (Pfizer / Eyetech Pharma)

Macugen® the first anti-VEGF inhibitor to be approved by the FDA for the treatment of wet age-related macular degeneration.

Array Biopharma (AstraZeneca)

ARRY-142886 is a novel, selective, non-ATP-competitive inhibitor of MEK and has demonstrated tumor suppressive or regressive activity in multiple preclinical models of human cancer, including melanoma, pancreatic, colon, lung and breast cancer models. Currently in Phase II trials.

Allos Therapeutics

Efaproxyn™ the first synthetic small molecule designed to sensitize hypoxic, or oxygen deprived, areas of tumors during radiation therapy by facilitating the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells, and increasing the level of oxygen in tumors. Currently in Phase III trials.

Replidyne (Daiichi Suntory / Asubio)

Faropenem® is the first oral penem antibiotic to reach an advanced stage of clinical development in the U.S. and is under development for community-acquired respiratory infections. Community antibiotics are generally used to treat infections acquired outside the hospital. Currently in Phase III trials.

Gilead (Myogen / GSK)

Ambrisentan® is a non-sulfonamide, propanoic acid-class, endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor. Activation of the ETA receptor by endothelin, a small peptide hormone, leads to vasoconstriction and cell proliferation. PAH is associated with elevated endothelin blood levels. Ambrisentan has been granted orphan drug designation for the treatment of PAH in both the United States and European Union. Currently in Phase III trials.

Gilead (Myogen / GSK)

Flolan® For primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA class III and class IV patients who do not respond adequately to conventional therapy.